Table 3 Demographic features, clinical manifestations, and treatment of SLE patients
SLE characteristics | Low Cognition (n = 48) | High Cognition (n = 33) | P Value |
|---|---|---|---|
Demographic | |||
 Age, (years) | 34.67 (±12.03) | 32.23 (±10.98) | 0.3530 |
 Females, n (%) | 40 (83.33%) | 30 (90.90%) | 0.763 |
 Education, (years) | 10.77 (±3.64) | 13.26 (±3.21) | < 0.01** |
 SLEDAI, mean ± (SD) | 13.91 (±11.79) | 9.38 (±5.79) | < 0.05* |
 Disease duration, (month) | 61.01 (±59.69) | 77.61 (±65.3) | 0.2486 |
Clinical chart review (%) | |||
 Rash, (%) | 10 (21.28%) | 6 (18.18%) | 0.768 |
 Mucosal ulcers, (%) | 2 (4.26%) | 1 (3.03%) | 1.000 |
 Haematuria, (%) | 22 (46.81%) | 13 (39.33%) | 0.510 |
 Proteinuria, (%) | 22 (46.81%) | 13 (39.33%) | 0.510 |
 Pyuria, (%) | 14 (39.79%) | 11 (33.33%) | 0.736 |
 Arthritis, (%) | 8 (17.02%) | 5 (15.15%) | 0.823 |
 Vasculitis, (%) | 4 (8.51%) | 0 (0%) | 0.231 |
 Pleurisy, (%) | 1 (2.13%) | 1 (3.03%) | 1.00 |
 Pericarditis, (%) | 1 (2.13%) | 0 (%) | 1.00 |
 Low complement, (%) | 36 (76.60%) | 27 (81.82%) | 0.574 |
 Anaemia, (%) | 11 (23.40%) | 1 (3.03%) | < 0.05* |
 Thrombocytopenia, (%) | 11 (23.40%) | 4 (12.12 | 0.203 |
 Leukopenia, (%) | 11 (23.40%) | 7 (21.21%) | 0.817 |
 Lupus nephritis, (%) | 19 (40.43% | 20 (60.61%) | 0.075 |
 Neurological disorder, (%) | 6 (12.77%) | 5 (15.15%) | 1.00 |
Current medication (%) | |||
 Prednisone (%) | 31 (64.58%) | 18 (54.54%) | 0.425 |
 Hydroxychloroquine (%) | 29 (61.70%) | 19 (57.58%) | 0.711 |
 Cyclophosphamide (%) | 5 (10.64%) | 3 (9.09%) | 1.000 |
 Azathioprine (%) | 1 (2.13%) | 1 (3.03%) | 1.000 |
 Methotrexate (%) | 2 (4.26%) | 2 (6.06%) | 1.000 |
 Cyclosporine (%) | 0 (0%) | 2 (6.06%) | 0.326 |